Introduction
This document is intended to provide guidance for the development and validation of software used in clinical genetics, focusing on bioinformatics pipelines for next-generation sequencing (NGS) applications. It is not meant to replicate the large amount of literature and best practice guidelines that already exist around software development or validation of clinical genetics diagnostic tests [1] [2] [3] [4] [5] [6] [7] . It aims to provide some baseline guidance for bioinformaticians and stakeholders in the NHS. It should be noted that any data analysis pipeline is just one part of a far larger clinical process; it is therefore both dependent on the quality of raw data and limited by the tools that are available.
Definitions
Shall = requirement [8] . Should = recommendation, i.e. there may exist valid reasons in particular circumstances to not follow a recommendation, but the full implications must be understood and carefully considered before choosing a different course [8] . Software = inclusive of everything from simple scripts to complex software packages.
Software/pipeline development
The principal of "write code for humans not machines" shall be adhered to [5] , including the use of extensive commenting, informative variable names etc. Benefits of developing a "house-style" should be considered and if adopted, this shall be enforced. Annotation within code shall be used for the benefit of other developers and as memory aids for the initial developer, including documenting purpose and rationale. Ongoing support for end users shall be considered, particularly when designing user interfaces, and user guides shall be provided. Contingency planning and other risk assessments shall be performed for all software critical for diagnostic testing. Attempts should be made to publish developed software where it is possible/appropriate to do so (an online repository such as GitHub [9] and/or bioarxiv.org [10] is sufficient).
A system of version control, e.g. Git [11] , shall be used for all software and/or scripts used to process diagnostic data. The version control system shall be used to record all changes, and informative commit messages shall be logged to aid traceability and audit. The versions of reference genome, annotation sources and other reference data shall also be recorded. Furthermore, the version control system shall allow recording releases/milestones so that the results of a diagnostic test can be unambiguously linked to the software and data sources that were used to generate them. The version control system shall be designed to work in a multiuser environment to aid teams of developers working together and to assist with transition of workforce.
High-level peer review of code shall be performed before any code is made live. This shall be carried out by a person other than the initial developer (assessed to be competent in this role) and documented. High-level code review shall include reviewing the purpose, the logic used to reach the goal and sanity checks of the output. A more in-depth system that includes raising issues (or change requests), implementing changes on a development branch, testing, performing code review at a line by line level, and then merging changes back to a master branch is preferable and should be implemented. An example of an in-depth system using Github [9] is shown in figure 1 . In addition to improving quality, code review shall also be used to facilitate training, assess competency and review staff performance. [11] 
Figure 1: An example workflow for version control and code review using Git

The use of external software
Diagnostic pipelines often contain a mix of software that has been developed in-house and externally, of which the latter can be further divided into open source, collaborative and commercial. When adopting to use external software, developers shall consider potential issues around documentation, support and updates, preferably using only heavily documented software with an active support network. Developers should avoid external, non-commercial software that has not been published following peer review. A system for regularly checking for software updates and bug fixes shall be adopted and documented. Any new version shall be validated before introduction into clinical service. The versions of any software used for diagnostic purposes shall be recorded and details of key software shall be included on the clinical report. The versions of reference genome, annotation sources and other reference data shall also be recorded.
Where external software is being used with settings different to those recommended or default, these shall be validated through a comparison with the recommended settings, using the validation dataset as described in the following section. Justification for use of the new settings shall be documented.
An example of a typical NGS analysis pipeline is shown in Figure 2 . Table 1 details examples of commonly used software. Table  1 .
Validation of NGS pipelines
Extensive validation processes shall be incorporated into software development for clinical diagnostics. The example of single nucleotide variant (SNV) calling using a pipeline developed in-house for constitutional rare disease diagnostics is used here for demonstration purposes; however, the principles outlined here are also applicable to wider situations.
Initial validation of pipeline
This shall be a "dry" validation using truth data to assess the pipeline's output against the truth set. This can be done using the Genome in a Bottle reference data [12] . Users should be aware that there are potential biases in this data towards regions that are easier to sequence with current NGS technologies, and also a potential bias towards current variant callers (e.g. the GATK suite [13] ). However, the data is useful as a baseline measure of sensitivity and specificity. A "wet" validation using Genome in a Bottle reference material 8398 [14] should also be considered.
The sensitivity of the pipeline shall be determined using clinical data, i.e. variants detected by Sanger sequencing as part of a diagnostic service which are then also identified with NGS. The resulting sensitivity should have a 95% confidence interval >0.95. This can be achieved if the NGS pipeline detects all 60 of 60 Sanger variants, with no false negatives [3] . In addition, detecting 300 of 300 will achieve a 95% 1 confidence interval >0.99. These variants shall be derived from at least 10 individuals.
It should be noted that comparison of called variants against a truth set is a non-trivial task in cases of indels and complex variation, due to alternative representations of variants in vcf files. Tools such as hap.py [15] and vcfeval [16] may be useful for normalisation and comparison of vcf files. There is a benchmarking task team within the Global Alliance for Genomics and Health that is developing further tools and standards [17] .
Further validation of pipeline
1 As per the referenced paper and in line with other guidelines, the "rule of three" is used to derive figures of 60 and 300 for 95% confidence intervals >0.95 and >0.99 respectively. However, laboratories are able to calculate confidence intervals for sensitivity (e.g. https://www.medcalc.org/calc/diagnostic_test.php), which is particularly useful when sensitivity is <100%.
Prior to any changes being merged into production code, a round of validation shall be performed as per the initial validation detailed above. Therefore, a validation dataset should be maintained to standardise and simplify this process.
Validation following substantive changes to a pipeline
If substantive changes are made to a pipeline, e.g. implementing a new variant caller to improve detection of indels, the existing dataset for validation shall be assessed for relevance and addition of further data shall be considered.
Laboratories may want to consider using data derived from a haploid cell line, e.g. CHM1 [18] [19] [20] , in some cases.
Summary
The guidelines presented here are intended to be useful to laboratories developing software for analysis of data generated by diagnostic tests, in particular bioinformatics pipelines for NGS data. It is important to note that these guidelines are for validation of software/pipelines and not the full diagnostic test; they should therefore be implemented in the context of other guidelines.
